A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1

A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L)

Published:2005-06 Issue:16_suppl Volume:23 Page:LBA7025-LBA7025
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Treat J.¹,Belani C. P.¹,Edelman M. J.¹,Socinski M. A.¹,Ansari R. H.¹,Obasaju C. K.¹,Bloss J. D.¹,Marinucci D. M.¹,Catalano R. B.¹,Comis R. L.¹

Affiliation:

1. Fox Chase Temple Cancer Ctr, Philadelphia, PA; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Maryland Greenebaum Cancer Ctr, Baltimore, MD; Univ of North Carolina, Chapel Hill, NC; Michana Hematology Oncology, PC, South Bend, IN; Lilly Oncology, Indianapolis, IN; Drexel Univ Coll of Medicine, Philadelphia, PA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2005.23.16_suppl.lba7025

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials;International Journal of Clinical Oncology;2012-12-06

2. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer;Critical Reviews in Oncology/Hematology;2011-05

3. A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer;Journal of Thoracic Oncology;2010-07

4. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer;Lung Cancer;2010-07

5. Adverse Events Among the Elderly Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer;Journal of Clinical Oncology;2010-02-01